Professor of Medicine, University Iowa College of Medicine
Hematology
Dr. George J. Weiner, MD
|
|
Give Review
George J. Weiner practices Hematology. He went to medical school at The Ohio State University College of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACP)". George J. Weiner is a published doctor. He published 101 publications, including: '5E10: a prostate-specific surface-reactive monoclonal antibody.' Doctor George J. Weiner, MD accepts Medicare.
Publications
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
- Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular Lymphoma in the immunochemotherapy era: a report from the University of Iowa...
- Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach.
- Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge.
- Intestinal Helminths Regulate Lethal Acute Graft-versus-Host Disease and Preserve the Graft-versus-Tumor Effect in Mice.
- Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region.
- Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer.
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell Lymphoma.
- Cancer Progress Report 2014.
- Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell Lymphoma.
- Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic Leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab ...
- Widespread use of complementary and alternative medicine among non-Hodgkin Lymphoma survivors.
- Complement in monoclonal antibody therapy of cancer.
- Genome-wide association study identifies multiple risk loci for chronic lymphocytic Leukemia.
- CXCR5 polymorphisms in non-Hodgkin Lymphoma risk and prognosis.
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-hodgkin Lymphoma.
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin Lymphoma.
- Cancer Immunotherapy Comes of Age.
- Manipulation of cellular redox metabolism for improving therapeutic responses in B-cell Lymphoma and multiple myeloma.
- A Phase I Clinical Trial of CpG Oligonucleotide 7909 (PF-03512676) in Patients with Previously Treated Chronic Lymphocytic Leukemia.
- Rituximab infusion induces NK activation in Lymphoma patients with the high affinity CD16 polymorphism.
- Vitamin D insufficiency and prognosis in chronic lymphocytic Leukemia.
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Making a better antibody: all is not lost.
- Cancer and inflammation: promise for biologic therapy.
- Rituximab: mechanism of action.
- Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion.
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal an...
- Measuring granulocyte and monocyte accumulation at malignant Lymphoma sites.
- A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular Lymphoma.
- Short telomeres in B-CLL: the chicken or the egg?
- CpG oligodeoxynucleotides as immunotherapy in cancer.
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
- A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
- Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's Lymphoma.
- Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
- Monoclonal antibody mechanisms of action in cancer.
- B-chronic lymphocytic Leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
- Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin Lymphoma.
- The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.
- Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic Leukemia cells.
- B-cell Lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
- Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic Leukemia.
- Cancer biology--lost in translation?
- Antibody therapy of Lymphoma.
- CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response.
- CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
- Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
- Persistent thrombocytopenia during remission in Acute leukemia does not preclude long-term disease-free survival.
- Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of Lymphoma.
- Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic Leukemia.
- Identification of candidate B-Lymphoma genes by cross-species gene expression profiling.
- Picking the Optimal Target for Antibody-Drug Conjugates.
- Hepatic failure from Hodgkin's disease in a patient with HIV infection.
- All that sticks is not a band-aid.
- The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.
- Mitochondria control of cell death induced by anti-HLA-DR antibodies.
- Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
- Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management.
- Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid.
- Active choice but not too active: public perspectives on biobank consent models.
- Systematic reviews of the effectiveness and cost-effectiveness of multi-channel unilateral cochlear implants for adults.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults.
- Bispecific antibodies in cancer therapy.
- Radiolabeled antibody imaging of patients with potentially resectable colorectal adenocarcinoma.
- Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell Lymphoma.
- Molecular characterization of anti-idiotype antibody-resistant variants of a murine B cell Lymphoma.
- The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379).
- 5E10: a prostate-specific surface-reactive monoclonal antibody.
- Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.
- Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell Lymphoma.
- Humanization and characterization of the anti-HLA-DR antibody 1D10.
- Uses of granulocyte-macrophage colony-stimulating factor in vaccine development.
- Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell Lymphoma.
- Treatment of relapsed or refractory Acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
- Introduction: bispecific antibodies.
- Bispecific IgG and IL-2 therapy of a syngeneic B-cell Lymphoma in immunocompetent mice.
- T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
- Immunostimulatory DNA sequences and cancer therapy.
- CpG DNA in cancer immunotherapy.
- Bone marrow morphology during induction phase of therapy for Acute myeloid leukemia (AML).
- Advances in the management of B-cell Lymphomas.
- The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility.
- Minimally differentiated Acute leukemia.
- HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
- Inhibition of Lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin recep...
- Bispecific monoclonal antibody therapy of B-cell malignancy.
- The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
- Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
- CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
- Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
- The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
- T-cell activation induced by anti-CD3 x anti-B-cell Lymphoma monoclonal antibody is enhanced by pretreatment of Lymphoma cells with soluble CD40 ligand.
- Good prognosis cytogenetics in B-cell chronic lymphocytic Leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity.
- APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
- CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine Lymphoma.
- Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Schools
Ohio State University College of Medicine
Med College Ohio
University Of Michigan
Conditions Treated
- Acute Leukemia
- Anemia
- Lymphoma
- Lymphosarcoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
Education
-
University of Michigan Hospitals and Health Centers -
The Ohio State University College of Medicine
Drug Facts
| NPI NUMBER | 1407826456 | |
| NPPES Provider LastName | WEINER | |
| NPPES Provider FirstName | GEORGE | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 60.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407826456 |
| Last Name Of The Provider | WEINER |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. Eric S. Engelman, DO |
|
|
Dr. Steven R. Lentz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel C. Marko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark W. El-Deiry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott D. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles P. Burns, MD |
|
|
Dr. Thorvardur R. Halfdanarson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laith I. Abushahin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori J. Rosenstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea O. Akpoguma, MD |
|
|
Dr. Daniel J. Berg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose P. Leone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Kuzman, MD |
|
|
Dr. Prerna Rastogi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark W. Karwal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sergei I. Syrbu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michel R. Nasr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grerk Sutamewagul, MD |